Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis

Amalia Penna, Diletta Laccabue, Irene Libri, Tiziana Giuberti, Simona Schivazappa, Arianna Alfieri, Cristina Mori, Diana Canetti, Pietro Lampertico, Mauro Viganò, Massimo Colombo, Elisabetta Loggi, Gabriele Missale, Carlo Ferrari

Research output: Contribution to journalArticle

Abstract

Background & Aims: The effect of IFN-α therapy on HBV-specific T-cell responses in HBeAg-negative, genotype D, chronic hepatitis B is largely undefined. Understanding to what extent IFN-α can modulate HBV-specific T-cells is important to define strategies to optimize IFN efficacy and to identify immunological parameters to predict response to therapy. Methods: HBV-specific T-cell responses were analyzed longitudinally ex vivo and after expansion in vitro in 15 patients with genotype D, HBeAg-negative chronic hepatitis B treated with peginterferon-α-2a. HBV proteins and synthetic peptides were used to stimulate T-cell responses. Analysis of the CD4 and CD8 T-cell functions was performed by ELISPOT, intracellular cytokine and tetramer staining. The effect of anti-PD-L1 on T-cell functions was also analyzed. Results: Ex vivo IFN-γ production by total HBV-specific T-cells was significantly greater before therapy in patients who showed HBV DNA

Original languageEnglish
Pages (from-to)1239-1246
Number of pages8
JournalJournal of Hepatology
Volume56
Issue number6
DOIs
Publication statusPublished - Jun 2012

Keywords

  • Adaptive immunity
  • Antiviral therapy
  • Cytokines
  • PD-1

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis'. Together they form a unique fingerprint.

Cite this